ProCE Banner Activity

Practical Insights for NPs and PAs: Biomarker Testing in NSCLC

Clinical Thought

Expert faculty discuss the importance of comprehensive molecular profiling in NSCLC and the impact of actionable biomarkers on treatment selection.

Released: June 05, 2023

Share

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Learning Objectives

  • Identify actionable biomarkers and their impact on non-small-cell lung cancer (NSCLC)

  • Integrate recommended approaches to biomarker testing into the management of patients with NSCLC

  • Utilize the results of biomarker testing to identify optimal treatment strategies for patients with advanced NSCLC

Disclosure

Primary Author

Rasheda Persinger, MSN, AGNP-C, AOCNP

Medical Oncology Lead Nurse Practitioner
Sidney Kimmel Cancer Center Sibley Memorial Hospital
Johns Hopkins System
Washington, DC

Rasheda Persinger, MSN, AGNP-C, AOCNP: consultant/advisor/speaker: AstraZeneca, Guardant Health.